

2026 Pharmacy Pearls for Prescribers - GLP Series

08/15/2026 to 08/15/2028

Enduring Material

Purpose:

Pharmacy Pearls for Prescribers provides up-to-date information on medications, developed by a multidisciplinary group of AMG primary care physicians and pharmacists from Avera Health and Avera Health Insurance Division. An interdisciplinary group has been working to develop educational materials to meet this need. In this series we will discuss anticoagulation management related to GLP Management

Objectives:

- 1 Compare available GLP-1 receptor agonists based on indications, efficacy, dosing schedules, and routes of administration
- 2 Apply evidence-based recommendations for initiating, titrating, and switching between GLP-1 receptor agonist therapies.
- 3 Identify common adverse effects associated with GLP-1 receptor agonists and implement strategies to improve tolerability and treatment adherence.
- 4 Evaluate patient-specific factors, including comorbidities, insurance coverage, and medication access barriers, when selecting GLP-1 receptor agonist therapy
- 5 Describe current recommendations regarding compounded GLP-1 products and patient counseling considerations.
- 6 Describe how a multidisciplinary approach can contribute to continuous and reliable patient care

Target Audience:

Physician, Nurse - RN, Pharmacist, Pharmacy Technician, Nurse -LPN/LVN

For successful completion:

- Read Pharmacy Pearl
- Complete pre and post-test
- Complete evaluation

Accreditation & Credit Designation:

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Education Credit Designation(s)



IPCE CREDIT™

IPCE (Team-based): This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.

Medicine CME: Avera designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Nurse CE: Avera designates this activity for a maximum of 1.00 ANCC contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

REMINDER

Attendance can be texted up to 24 hours after the activity



Nursing Pharmacotherapeutic

This activity has been approved for 1.00 pharmacotherapeutic credit(s).

Pharmacy CE: Avera designates this activity for 1.0 ACPE contact hour(s). ACPE Universal Activity Number (UAN): JA0008079-0000-26-051-H01-P / JA0008079-0000-26-051-H01-T. Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be uploaded to the NABP CPE Monitor within 30 days after the activity completion. Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and DOB (MMDD)) to receive credit.

Additional Information:

Feedback person for this educational activity is:

Enduring Material available from 08/15/2026 to 08/15/2028

- This course content was reviewed on 08/07/2026

Disclosure Policy:

Due to the regulations required for CE credits, all conflicts of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement, we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Kelly Boyd, MSN, Nurse	Lead Planner	Nothing to disclose
Breanna Brungardt, Pharm	Committee Planning Member	Nothing to disclose
Christine M. Burg, PharmD, Pharmacist	Committee Planning Member	Nothing to disclose
Rachelle Davis, Pharm, Pharmacist	Content Expert - Committee Member	Nothing to disclose
Brittni Franken, PharmD	Faculty	Nothing to disclose
Allison 4472 Hein 4972, PharmD	Committee Planning Member	Nothing to disclose
Patrick Huska, PharmD	Committee Planning Member	Nothing to disclose
Rebecca Moore, PharmD	Committee Planning Member	Nothing to disclose
Donald Odens, MD	Committee Planning Member	Nothing to disclose
Denise Page, BS	Committee Planning Member	Nothing to disclose
Amy Ross, Pharm, Pharmacist	Committee Planning Member	Nothing to disclose
Samantha Scheich, PharmD, Pharmacist	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Sanofi-Aventis (Relationship has ended)
Chad Thury, DO	Content Expert - Committee Member	Nothing to disclose
Marah Van Diest, MD	Committee Planning Member	Nothing to disclose
Emily Van Klompenburg, PharmD	Content Expert - Committee Member, Lead Planner	Nothing to disclose
Beau (6042) VanOverschelde, PharmD	Committee Planning Member	Nothing to disclose

REMINDER

Attendance can be texted up to 24 hours after the activity